Exosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma

Key Points

• Findings indicate that exosomal ANGPTL2 in cerebrospinal fluid serves as an independent prognostic marker for PCNSL.
• CSF exosomal ANGPTL2 levels were strongly associated with patient outcomes in a cohort study of PCNSL.
• Observational analysis of cerebrospinal fluid samples demonstrated the prognostic value of ANGPTL2 for patient survival.
• These results highlight the potential for exosomal ANGPTL2 to guide treatment decisions in PCNSL cases.

Abstract